all4cure presentation for wsmos april 6, 2018 - final presentation for wsmos... · 2018-04-06 ·...
TRANSCRIPT
All4Cure’s Knowledge Sharing Platform A Revolutionary Tool for Adaptive Learning in Medicine
Washington State Medical Oncology SocietyApril 6, 2018
Tony Blau, MDFounder and CEO
April 9, 2015
My Cancer Decision Tree
>95% of Information from Treating Disease is Lost
Fewer than 5% of patients participate in clinical trials
All4Cure can capture information from all patients
Our initial focus is in a form of blood cancer (myeloma)
About UsTony Blau, MD• CEO, All4Cure• Professor of Medicine/Hematology for 29 years at the University of Washington
(currently on leave of absence).• Co-‐Founder/Co-‐Director, Institute for Stem Cell and Regenerative Medicine• Founder/Director, Center for Cancer Innovation
Ricardo Lopez Barquilla, PhD• CTO, All4Cure• General Manager of Devices at Microsoft, leading a group of 600 engineers
responsible for Surface® and XBOX®.
Established Proof of Concept
Launched March 2017.
Today: 442 registered users>270 Patients>35 Clinicians>35 Researchers
Process: Step 1: Register (free) Step 2: Patients provide access to their medical records
Graph capturespatient’s experience with cancer, correlating treatments with responses.Hovering over icons reveals treatments and lab values
Posts enable focused, patient – centereddiscussions by All4Cureparticipants
Documents Panel allows physician notes or reportsto be uploaded
Unique Patient ID
Entire Patient Journey
360oView of the
Patient Journey
MEDICAL RECORDS
PATIENT REPORTED OUTCOMES
Example 1: Bringing a Distributed Network of Experts to a Single Patient
61 year old retired flight attendant
Developed tumor cells in the
cerebrospinal fluid
Dr. Travis QuigleyBluebird Bio, Cambridge MA Dr. Bill Bensinger,
Swedish Medical Center, SeattleDr. Ken Anderson,
Dana Farber Cancer Institute/Harvard
Dr. Ken Anderson,Dana Farber Cancer Institute/Harvard
One Patient, One Suggestion = Massive Impact
Myeloma Cells in the CSF? Think Marizomib
Benefits ALL PatientsACCELERATES ENROLLMENT INTO CLINICAL TRIALS
Example 2: Accelerating Diagnostic Testing and Clinical Trials
53 year old resident of NYC
All4Cure assisted with molecular testing -‐> Identified BRAFV600E
Mutation
All4Cure identified a clinical trial targeting BRAFV600E in NYC
Molecular Diagnostics and Pharmaceutical Companies Benefit
All4Cure Patients
Effective Strategy (e.g. Clinical Trial of Marizomib for CNS Myeloma, or
BRAF/MEK inhibitors for BRAFV600E myeloma)
Excellent Response
+++
Oncologists and Patients Seek Enrollment
Ripple Effect: One Patient’s Experience Can Have a Massive Impact Across All4Cure’s Network
0
500
1000
1500
2000
2500
3000
3500
4000
MM-‐2
16
MM-‐2
13
MM-‐2
11
MM-‐1
07
MM-‐1
05
MM-‐1
03
MM-‐2
20
MM-‐6
8MM-‐4
3MM-‐4
0MM-‐2
06
MM-‐1
3MM-‐4
5MM-‐4
8MM-‐6
4MM-‐2
9MM-‐2
39
MM-‐4
9MM-‐1
1MM-‐6
5MM-‐8
6MM-‐8
3MM-‐8
0MM-‐1
30
MM-‐1
58
MM-‐1
77
MM-‐2
25
MM-‐1
39
MM-‐2
04
MM-‐1
23
MM-‐9
MM-‐8
MM-‐2
02
MM-‐5
MM-‐4
MM-‐7
MM-‐1
16
MM-‐1
MM-‐2
MM-‐5
3MM-‐5
2MM-‐5
5MM-‐5
4MM-‐1
92
MM-‐7
7MM-‐7
6MM-‐7
5MM-‐7
4MM-‐7
0MM-‐1
87
MM-‐3
7MM-‐1
84
MM-‐3
5MM-‐1
2MM-‐9
5MM-‐1
43
MM-‐1
46
MM-‐1
47
MM-‐1
44
MM-‐1
64
MM-‐1
60
MM-‐1
61
MM-‐1
62
DAYS OF REVLIMID TREATMENTALL4CURE DATA COLLECTION DEC'17
Duration of Revlimid treatment (days) across Patients Enrolled in All4Cure (Dec 17)
MM-‐35 Received Revlimid for a Decade
MM-‐180 Also Received Revlimid for a Decade
Both MM-‐35 and MM-‐180 have t(4:14)
All4Cure Empowers Patients
Democratization of Knowledge – Patients will eventually be able to see how their treatments compare to those of thousands of other patients with the same or similar condition.
All4Cure is a Patient Education Tool
And Can Capture Patient Reported Outcomes
BortezomibLenalidomide
DexamethasoneCarfilzomibPomalidomide
M-‐Spike
MelphalanAutologous SCT
MM-‐8
Reimbursement Decisions – Denial of Payment for Car/Pom/Dex
DexamethasoneCarfilzomibPomalidomide
MelphalanAutologous SCT
M-‐Spike
MM-‐77’s Oncologist is Employing the Same Strategy as MM-‐8’s Oncologist
Appeal Approved!
The Power of Collective Experience
Today, decisions regarding treatment and reimbursement are based on publications and guidelines (NCCN, ASCO, etc).
But what if these decisions could be based on the results of our collective experience?
Patients Benefit…Before All4Cure patients could…
• Request their medical records.
• View lab results through patient portals.
• Read about their disease, including treatment options and prognosis.
• Read about new developments relevant to their disease.
• Consult their doctor. Seek second or third opinions.
• Participate in disease-‐related social media platforms.
With All4Cure patients can…
• Access a comprehensive, easy to understand graph that summarizes their experience with cancer.
• Compare their tests, treatments and responses to those of other patients.
• Request other information or suggestions relevant to their specific situation.
Oncologists Benefit …
Before All4Cure oncologists could…
• Review their patient’s medical records.
• Read books, journals, access NCCN, ASH, ASCO guidelines, subscribe to UpToDate, attend national meetings
• Present patients at tumor boards.
• Consult colleagues, or refer their patients for second opinions.
With All4Cure oncologists can…
• Access a comprehensive graph portraying their patient’s experience with cancer.
• Access the graphs of other patients facing the same or similar problems.
• Observe how their treatment decisions compare with those of other oncologists.
• Review suggestions from other participants that may be relevant to their patients.
• Request input from other participants.
We Want to Work with YOU!
Register at https://www.all4cure.com
Please contact us:[email protected](206) 412-‐1787
Next Steps:
Scale Up – Community Oncology Practices
Build Commercial Partnerships – Business intelligence, Phase 4 monitoring (safety, efficacy, optimal use).
Researchers
Patients Clinicians
All4Cure’s Knowledge Sharing Platform
Is an Engine for Adaptive Learning